Project Details
Description
A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 (200 mg BID) for 10 days
Status | Finished |
---|---|
Effective start/end date | 6/17/14 → 12/31/15 |
Funding
- SUMMIT PLC